Please upgrade your browser.
Trial Principal Investigator Dr Thomas E Hutson of the Baylor Sammons Cancer Centre/Texas Oncology commented The mechanism of action of BNC105 provides an innovative approach to the treatment of solid tumours, including metastatic renal carcinoma, by attacking established tumour vasculature. It is particularly exciting to be conducting a trial which has the potential of creating a new paradigm for the treatment of renal cancer.
Rexahn has yet to enroll a single patient in a phase II study of its experimental cancer drug Archexin in advanced kidney cancer. Rexahn announced the start of this Archexin study in May 2007! Since then, the number of patients enrolled equals zero -- as in zilch, nada.
Using renal mass biopsy to guide treatment decisions for small tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers.
According to board member Janelle Mungo, ATOs contract with Twiin stipulates that after the $16,500 the board funded is donated to the Kidney Cancer Association, 75 percent of ticket sales will be given to Twiin.
There is no traditional training path into medical informatics, notes Eric Perakslis [director, Kidney Cancer Association], vice president for research and development informatics at Johnson & Johnson Pharmaceutical Research and Development L.L.C. in Titusville, New Jersey. In fact, if you talk to 10 people in medical informatics, you'll probably hear 10 different stories about how they got there. Physicians, nurses, pharmacists, and computer engineers all find their way into the field.
Dr. Bruce Varley: (Zachary Knighton) When the flash knocked everyone out, it stopped Bruce from committing suicide after hearing a diagnosis of stage four kidney cancer.
Several additional angiogenesis inhibitors are expected reach the market in the next five years. Compounds to watch include Pfizer's SU-11248, which has demonstrated efficacy in imatinib-resistant gastrointestinal stromal tumors; Bayer and Onyx Pharmaceuticals BAY-43-9006, which is in Phase III for renal cell carcinoma; and Genentech and Novartis's ranibizumab (Lucentis) for AMD.
Jesse said that his dad fought the disease, but it was a difficult process to be a part of. Kidney cancer occurs roughly twice as often in males as in females, according to Kidney Cancer Association. Fifteen to 25 percent of patients have metastatic disease at the time of their diagnosis, meaning their cancer has spread to other areas of the body.
|NeonCRM by Neon One|